Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The project aims to achieve significantly improved clinical care for type 2 diabetes. The current standard treatment metformin has low adherence due to its main side effect gut dysbiosis, which also results in more complications and high overall costs. Prebiotics have been suggested as a medical food and might be helpful as adjuvant management in type 2 diabetes and other metabolic diseases. Carbiotix AB has developed, a corn fiber extract containing arabinoxylan-oligosaccharides (AXOS), which have great potential for improving gut health. In this project, it will be investigated whether the intake of a hybrid product containing AXOS together with metformin can significantly improve glucose metabolism and gut health in patients with type 2 diabetes.
Epistemonikos ID: e432f7b6a243985e6adc71aadc409458c1417e5f
First added on: Feb 19, 2024